Your Cholesterol Number May Not Tell the Whole Story

Why Advanced Heart Risk Testing May Be One of the Most Important Preventive Health Conversations This Year

For decades, patients have been told to “check your cholesterol.” Most people know their LDL cholesterol, often called “bad cholesterol,” and HDL cholesterol, often called “good cholesterol.” But the newest cholesterol guidance from the American College of Cardiology and American Heart Association makes something very clear: traditional cholesterol testing is important, but it may not tell the whole story.

The updated 2026 cholesterol guideline emphasizes a more personalized approach to cardiovascular prevention, including earlier treatment, clearer LDL cholesterol goals, and selective use of additional tests such as coronary artery calcium scoring, Lipoprotein(a), and Apolipoprotein B. These tools can help identify hidden cardiovascular risk before a heart attack or stroke occurs.

At Beverly Hills Institute, this is exactly the kind of prevention we discuss during an Annual Wellness Visit: not just whether your cholesterol is “normal,” but whether your overall cardiovascular risk is truly being understood.

Why “Normal Cholesterol” Can Be Misleading

A standard lipid panel usually includes total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. These numbers are very useful, but they do not always fully capture a patient’s true risk.

Two people can have the same LDL cholesterol level but very different risk profiles. One may have no plaque in the arteries, while the other may already have early coronary artery disease. One may have a strong family history of heart attack. Another may have diabetes, elevated inflammatory risk, high triglycerides, or a genetically elevated Lipoprotein(a).

That is why modern preventive medicine is moving beyond simply asking, “Is your cholesterol high?” and instead asking, “What is your actual risk of developing plaque, heart attack, or stroke?”

LDL Goals Are Back

One of the most important updates in the 2026 guideline is the return of LDL cholesterol treatment goals.

For prevention of a first heart attack or stroke, the guideline identifies LDL-C goals based on risk level. For many patients at borderline or intermediate risk, the LDL-C goal is less than 100 mg/dL. For high-risk patients, the goal is less than 70 mg/dL. For patients with known cardiovascular disease who are at very high risk, the goal may be less than 55 mg/dL.

This matters because cardiovascular disease is not something that suddenly appears at age 65. Plaque builds over years and decades. The earlier we identify risk, the more opportunity we have to intervene with lifestyle, nutrition, exercise, weight management, blood pressure control, diabetes prevention, and when appropriate, medication.

Coronary Artery Calcium Scan: Seeing Plaque Before Symptoms

A coronary artery calcium scan, often called a CAC scan, is a low-radiation CT scan that looks for calcified plaque in the coronary arteries. It does not require contrast dye, and it can help determine whether a patient already has early evidence of coronary artery disease.

The new guideline supports selective use of CAC scoring in men age 40 and older and women age 45 and older who have borderline or intermediate 10-year cardiovascular risk when the result would help guide a decision about statin therapy. Any amount of coronary artery calcium supports a more serious discussion about LDL lowering, with lower LDL goals recommended as the calcium score increases.

In practical terms, this test can be very helpful for patients who say:

“My cholesterol is borderline, but I don’t want to take medication unless I really need it.”

Or:

“My cholesterol does not look that bad, but heart disease runs in my family.”

A CAC scan can help move the conversation from guesswork to evidence.

Lipoprotein(a): The Genetic Risk Many Patients Have Never Checked

Lipoprotein(a), or Lp(a), is a cholesterol-related particle that is largely genetically determined. Unlike LDL cholesterol, it is not significantly changed by diet, exercise, or weight loss. That does not mean lifestyle is unimportant. It means that if Lp(a) is high, we need to know about it so we can manage the rest of the patient’s risk more aggressively.

The 2026 guideline states that Lp(a) should be measured at least once in adulthood. A high Lp(a), defined as 125 nmol/L or greater or 50 mg/dL or greater, is associated with increased long-term risk of heart attack and stroke. Very high levels are associated with even greater risk.

This is especially important for patients with:

A family history of early heart diseaseA personal history of unexplained cardiovascular diseaseHigh cholesterol despite a healthy lifestyleAortic valve diseaseA heart attack or stroke at a younger age

Many patients with elevated Lp(a) have no idea they carry this risk because it is not included in a routine cholesterol panel.

Apolipoprotein B: Counting the Dangerous Particles

Apolipoprotein B, or ApoB, is another advanced marker that can help refine cardiovascular risk. ApoB reflects the number of atherogenic particles in the blood, meaning the particles that can enter the artery wall and contribute to plaque formation.

In some patients, LDL cholesterol can look acceptable while ApoB remains elevated. This is more common in people with insulin resistance, metabolic syndrome, diabetes, high triglycerides, obesity, or cardiovascular-kidney-metabolic risk.

The guideline notes that ApoB may be useful to assess residual cardiovascular risk and guide treatment in certain patients, particularly those with type 2 diabetes, high triglycerides, cardiovascular-kidney-metabolic syndrome, or known cardiovascular disease.

In other words, ApoB may help answer a more precise question: how many plaque-forming particles are actually circulating in the bloodstream?

Prevention Is No Longer One-Size-Fits-All

The most important message from the new cholesterol guidance is that prevention should be personalized.

For some patients, a standard lipid panel and healthy lifestyle counseling may be enough. For others, especially those with family history, metabolic risk, diabetes, elevated triglycerides, obesity, inflammatory conditions, or unclear risk, additional testing can provide a much clearer picture.

This does not mean every patient needs every test. It means the right patient should get the right test at the right time.

What We Discuss During an Annual Wellness Visit

At Beverly Hills Institute, preventive care is not just about checking boxes. During an Annual Wellness Visit, we review cardiovascular risk in a more complete way, including:

• Blood pressureCholesterol and triglycerides

• Blood sugar and insulin resistance risk

• Weight, waist circumference, and body compositionFamily historySmoking history

• Sleep, stress, nutrition, and exercise

• Medication options when appropriate

• Advanced testing such as CAC score, Lp(a), and ApoB when clinically useful

  
  

The goal is not simply to treat a number. The goal is to prevent the heart attack, stroke, hospitalization, disability, or loss of quality of life that may occur years later if risk is missed.

The Bottom Line

Your cholesterol panel is important, but it may not be enough.

The newest cholesterol guideline reinforces what preventive physicians have been seeing for years: cardiovascular risk is more complex than a single LDL number.

Coronary artery calcium scoring, Lipoprotein(a), and Apolipoprotein B can help uncover hidden risk and guide a more personalized prevention plan.

If you have a family history of heart disease, borderline cholesterol, diabetes, high triglycerides, elevated blood pressure, weight concerns, or simply want a deeper understanding of your long-term health, this is a conversation worth having.

At Beverly Hills Institute, our goal is to help patients live longer, healthier, and better lives by identifying risk early and creating a prevention plan that is personalized, proactive, and based on the latest science.